Why is Telix Pharmaceuticals stock sliding today?

Telix Pharmaceuticals' stock slid 6.7% to A$16.66 on Monday following the announcement of a binding deal to acquire ITM Isotope Technologies Munich SE for US$1.65 billion. The transaction, which involves the issuance of approximately 105.8 million new shares and the assumption of US$302 million in ITM net debt, has raised concerns among investors about potential dilution and Telix's elevated valuation multiples.

Despite ITM's profitable isotope business, the acquisition at roughly six times ITM's 2025 revenue is seen as a financial stretch for Telix, which remains cash-flow negative. The broader Australian equity market also failed to provide support for Telix's decline.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.